Psychedelic Alpha published a research paper by Dr. Edward Jacobs and Dr. Bryony Insua-Summerhays in The Ethics Corner for The Psychedelic Practitioner's Special Issue on Preparedness.
Public source
Publisher name
Public post
“The workforce problem is not simply arithmetical, because the key deliverable for psychedelic therapy going mainstream isn’t just the right number of certified practiti…
Company
Psychedelic Alpha
The leading independent, data-driven voice in psychedelics.
- Industry
- Business Consulting and Services
- Location
- London, GB
- Company size
- 2–10 employees
About Psychedelic Alpha
The definitive resource for analysis of the emergent psychedelic medicine sector. Cut through the noise with exclusive news, interviews, data and opportunities.
See moreLatest activity
Latest activity from Psychedelic Alpha
13 signals
Strategy & Corporate Development
Psychedelic Alpha completed the acquisition of Psychedelic Drug Developer AtaiBeckley by Eli Lilly and Company for a total value of up to $3.8 billion.
Research & Knowledge
Psychedelic Alpha published an overview entry exploring anticipating psychedelic REMS programs, further considerations, shared REMS, REMS as competitive strategy, impact on patient access, off-label use, and drug scheduling.
Legal & Regulatory
Psychedelic Alpha reported that New Zealand’s Medsafe approved two Kiwi psychiatrists to prescribe and administer MDMA for PTSD.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Multidisciplinary Association for Psychedelic Studies (MAPS)
Multidisciplinary Association for Psychedelic Studies (MAPS) published a new JAMA Network Open study highlighting a gap in how safety is currently monitored within Oregon’s regulated psilocybin program.
Research & Knowledge
DELPHI
DELPHI expanded the literature on Blossom, including a broader full catalogue of psychedelic research covering research across psychedelics including MDMA and ketamine.
Research & Knowledge
Psychedelic Support
Psychedelic Support is recruiting participants for a study on psych*edel experiences and attitudes toward death in adults aged 40 and over, involving a 25-30 minute anonymous online survey and UCL Research Ethics Committee approval.
Research & Knowledge
Sunstone Therapies
Sunstone Therapies contributed clinical data from a psilocybin-assisted therapy study for people with cancer and major depressive disorder, co-authored by Sunstone Therapies researchers Sunstone Therapies Manish Agrawal, MD and Kimberly Roddy, MBA.
Research & Knowledge
EntheaCare